Craig-Hallum analyst Matt Hewitt raised the firm’s price target on BioLife Solutions to $30 from $23 and keeps a Buy rating on the shares. Overall, BioLife delivered a good Q2 report, the firm notes. In April, the company announced plans to divest its freezer business due to its negative impact on financial performance. Now that the divestiture is complete, the positive effects are evident in BioLife’s Q2 results, with gross margins improving by 15% year-over-year, Craig-Hallum says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS:
- BioLife Solutions price target raised to $28 from $26 at Northland
- BioLife Solutions raises 2024 revenue view to $99.0M-$101.0M from $95M-$100M
- BioLife Solutions reports Q2 cont-op EPS (16c), consensus (14c)
- BioLife Solutions Reports Second Quarter 2024 Financial Results
- BLFS Upcoming Earnings Report: What to Expect?